|M&A in the Pharmaceutical Contract Manufacturing Industry 2015-2017: Implications and Outlook - 2018 Report - ResearchAndMarkets.com|
|Friday, 11 January 2019 01:06|
Jan. 11, 2019 11:39 UTC
M&A in the Pharmaceutical Contract Manufacturing Industry 2015-2017: Implications and Outlook - 2018 Report - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)-- The "PharmSource - M&A in the Contract Manufacturing Industry: Implications and Outlook - 2018 Edition" report has been added to ResearchAndMarkets.com's offering.
The report "PharmSource - M&A in the Contract Manufacturing Industry: Implications and Outlook - 2018 Edition" analyzes merger and acquisition (M&A) activity in the pharmaceutical contract manufacturing industry during the period 2015-2017. The services considered in this report are contract manufacturing of active pharmaceutical ingredients (APIs) and finished dose products, associated analytical services, and packaging. Contract research providers were excluded.
Mergers and Acquisitions of companies and facilities have been a high profile feature of the pharmaceutical CMO industry in current times. Acquisition deals consistently receive high profile coverage in industry news media, with questions surrounding valuations, strategic intent and which companies are potentially next targets continuously debated in the industry.
There were 130 acquisitions of service providers during the three-year period from 2015-2017. The majority of acquisitions targeted contract manufacturing organizations (CMOs) that focused on APIs-small molecule, dose, and analytical services. Nearly 70% of acquirers of services companies were strategic acquirers, that is, they were operating companies rather than investment firms. A few services companies changed hands as a consequence of the purchase of their parent company, while several CMOs were acquired by bio/pharma companies seeking to secure product supply.
More than half of acquirers were public companies, although 36% of company acquisitions were by PE firms or by CMOs owned by PE firms, with a high level of influence on the industry. Companies with complex technologies, including biologics manufacturing, are likely to be sought-after targets, as well as CMOs with specialized capabilities. However, in the coming years, M&A activity will be hindered by higher interest rates, uncertain trade and investment policies, high valuation expectations, and sizeable debt loads carried by some of the most active acquirers.
Key Topics Covered:
1. Executive Summary
2 Objectives and Methodology
3 Overview of M&A Activity 2015-2017
4 Segment Close-Ups of M&A Activity, 2015-2017
6 Facility Acquisitions
7 What It Means
8 The Outlook for M&A in the Manufacturing Services Industry
For more information about this report visit https://www.researchandmarkets.com/research/f2hrx5/manda_in_the?w=4
Source: Research and Markets